Vicki Sato - Bristol Myers Lead Independent Director
| BMY Stock | USD 48.28 0.84 1.71% |
Director
Dr. Vicki L. Sato, Ph.D., serves as Lead Independent Director of BristolMyers Squibb Company since 2017.
| Age | 71 |
| Tenure | 7 years |
| Professional Marks | Ph.D |
| Address | Route 206 & Province Line Road, Princeton, NJ, United States, 08543 |
| Phone | 609 252 4621 |
| Web | https://www.bms.com |
Vicki Sato Latest Insider Activity
Tracking and analyzing the buying and selling activities of Vicki Sato against Bristol Myers stock is an integral part of due diligence when investing in Bristol Myers. Vicki Sato insider activity provides valuable insight into whether Bristol Myers is net buyers or sellers over its current business cycle. Note, Bristol Myers insiders must abide by specific rules, including filing SEC forms every time they buy or sell Bristol Myers'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Vicki Sato over two months ago Disposition of 1666 shares by Vicki Sato of Denali Therapeutics at 18.37 subject to Rule 16b-3 |
Bristol Myers Management Efficiency
The company has Return on Asset of 0.0563 % which means that on every $100 spent on assets, it made $0.0563 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.2653 %, implying that it generated $0.2653 on every 100 dollars invested. Bristol Myers' management efficiency ratios could be used to measure how well Bristol Myers manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Bristol Myers' Return On Capital Employed is fairly stable compared to the past year. Return On Assets is likely to rise to 0.14 in 2024, whereas Return On Tangible Assets are likely to drop 0.15 in 2024. At this time, Bristol Myers' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 66.6 B in 2024, whereas Other Assets are likely to drop slightly above 3.3 B in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Susan Sholtis | PetIQ Inc | 51 | |
| Sue Bailey | Emergent Biosolutions | 76 | |
| Larry Bird | PetIQ Inc | 63 | |
| Ronald Richard | Emergent Biosolutions | 64 | |
| Gary Michael | PetIQ Inc | 77 | |
| Alfred Sandrock | Neurocrine Biosciences | 60 | |
| Scott Huff | PetIQ Inc | 46 | |
| Stephen Sherwin | Neurocrine Biosciences | 69 | |
| Mark First | PetIQ Inc | 53 | |
| Joseph Mollica | Neurocrine Biosciences | 59 | |
| Seamus Mulligan | Emergent Biosolutions | 58 | |
| Louis Sullivan | Emergent Biosolutions | 86 | |
| Kathryn Zoon | Emergent Biosolutions | 71 | |
| Gary Lyons | Neurocrine Biosciences | 66 | |
| George Morrow | Neurocrine Biosciences | 66 | |
| James Clarke | PetIQ Inc | 45 | |
| George Joulwan | Emergent Biosolutions | 80 | |
| Ronald Kennedy | PetIQ Inc | 71 | |
| Will Santana | PetIQ Inc | 45 | |
| Richard Pops | Neurocrine Biosciences | 56 | |
| Jerome Hauer | Emergent Biosolutions | 68 | |
Management Performance
| Return On Equity | 0.27 | ||||
| Return On Asset | 0.0563 |
Bristol Myers Squibb Leadership Team
Elected by the shareholders, the Bristol Myers' board of directors comprises two types of representatives: Bristol Myers inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bristol. The board's role is to monitor Bristol Myers' management team and ensure that shareholders' interests are well served. Bristol Myers' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bristol Myers' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jitendra Tyagi, Head India | ||
| Togo West, Independent Director | ||
| Adam Dubow, Senior Vice President, Chief Compliance Officer and Ethics Officer, Member of the Leadership Team | ||
| Michael Bonney, Independent Director | ||
| Alan Lacy, Independent Director | ||
| Robert Bertolini, Independent Director | ||
| Catherine Owen, Senior Markets | ||
| Jose Baselga, Independent Director | ||
| Michael Grobstein, Independent Director | ||
| Phyllis Yale, Independent Director | ||
| John Elicker, Senior Vice President - Corporate Affairs and Investor Relations | ||
| BCH BM, Ex Devel | ||
| Karen Santiago, Senior Vice President, Corporate Controller | ||
| Rupert Vessey, Executive Vice President - Research and Early Development, Member of the Leadership Team | ||
| Giovanni Caforio, Chairman of the Board, Chief Executive Officer | ||
| Emmanuel Blin, Senior Vice President Chief Strategy Officer | ||
| Nadim Ahmed, Executive Vice President and President - Hematology | ||
| Joseph Caldarella, Senior Vice President Corporate Controller | ||
| Murdo Gordon, Executive Vice President Chief Commercial Officer | ||
| Cari Gallman, VP Officer | ||
| Lamberto Andreotti, Executive Chairman, Officer, Ex-Officio Member of Audit Committee, Ex-Officio Member of Committee on Directors and Corporate Governance and Ex-Officio Member of Compensation and Management Devel. Committee | ||
| Matthew Emmens, Independent Director | ||
| Ann Judge, Chief Human Resource Officer, Senior Vice President Member of the Leadership Team | ||
| Sandra Leung, Executive Vice President, General Counsel, Member of the Leadership Team | ||
| Ahn Poole, Executive Officer | ||
| Paul Autenried, Executive Vice President, Chief Information Officer, Member of the Leadership Team | ||
| Samit Hirawat, Executive Vice President, Chief Medical Officer, Global Drug Development, Member of the Leadership Team | ||
| Tim Power, Vice President of Investor Relations | ||
| Giovanni MD, Executive Board | ||
| Francis Cuss, Executive Vice President Chief Scientific Officer | ||
| Paul Biondi, Senior Vice President, Head of Strategy & Business Development | ||
| Greg Meyers, Executive Vice President Chief Digital and Technology Officer, Member of the Leadership Team | ||
| Kathryn Metcalfe, Executive Vice President - Corporate Affairs Member of the Leadership Team | ||
| Peter Arduini, Independent Director | ||
| Michelle Weese, Executive Vice President - Corporate Affairs, Member of the Leadership Team | ||
| Joseph Eiden, Head Affairs | ||
| Elizabeth Mily, Executive Vice President - Strategy and Business Development, Member of the Leadership Team | ||
| Ann Powell, Chief Human Resource Officer, Senior Vice President, Member of the Leadership Team | ||
| Karen Vousden, Independent Director | ||
| Paula Price, Independent Director | ||
| Charles Bancroft, Chief Financial Officer, Executive Vice President - Global Business Operations | ||
| Gerald Storch, Independent Director | ||
| Sandra Esq, Executive Counsel | ||
| Louis Schmukler, Executive Vice President, President - Global Product Development and Supply, Member of the Leadership Team | ||
| Christopher Boerner, Executive Vice President and Chief Commercial Officer, Member of the Leadership Team | ||
| Kimberly Jablonski, Chief Officer | ||
| David Elkins, Executive Vice President and Chief Financial Officer Member of the Leadership Team | ||
| Anne Nielsen, Senior Vice President Chief Compliance and Ethics Officer | ||
| Vicki Sato, Lead Independent Director | ||
| Manuel Medina, Independent Director | ||
| Julia Haller, Independent Director | ||
| Laurie Glimcher, Independent Director | ||
| Joseph Eid, Senior Vice President and Head of Global Medical Affairs, Member of the Leadership Team | ||
| Thomas Lynch, Chief Scientific Officer, Executive Vice President | ||
| Derica Rice, Independent Director | ||
| Lewis Campbell, Independent Director | ||
| Dinesh Paliwal, Independent Director | ||
| Theodore Samuels, Lead Independent Director | ||
| Samuel Moed, Senior Vice President - Strategic Planning and Analysis | ||
| Timothy Power, VP Relations | ||
| Adam Lenkowsky, Chief VP | ||
| Samit MD, Executive Development |
Bristol Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Bristol Myers a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.27 | ||||
| Return On Asset | 0.0563 | ||||
| Profit Margin | 0.18 % | ||||
| Operating Margin | 0.17 % | ||||
| Current Valuation | 126.93 B | ||||
| Shares Outstanding | 2.03 B | ||||
| Shares Owned By Insiders | 0.10 % | ||||
| Shares Owned By Institutions | 78.89 % | ||||
| Number Of Shares Shorted | 35.12 M | ||||
| Price To Earning | 24.88 X |
Pair Trading with Bristol Myers
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bristol Myers position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bristol Myers will appreciate offsetting losses from the drop in the long position's value.Moving together with Bristol Stock
| 0.76 | A | Agilent Technologies Financial Report 28th of May 2024 | PairCorr |
Moving against Bristol Stock
| 0.59 | BNR | Burning Rock BiotechLtd Financial Report 4th of June 2024 | PairCorr |
| 0.46 | DNA | Ginkgo Bioworks Holdings Financial Report 8th of May 2024 | PairCorr |
| 0.43 | VRTX | Vertex Pharmaceuticals Financial Report 6th of May 2024 | PairCorr |
The ability to find closely correlated positions to Bristol Myers could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bristol Myers when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bristol Myers - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bristol Myers Squibb to buy it.
The correlation of Bristol Myers is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bristol Myers moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bristol Myers Squibb moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bristol Myers can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bristol Myers Squibb. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Complementary Tools for Bristol Stock analysis
When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |
Is Bristol Myers' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bristol Myers. If investors know Bristol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bristol Myers listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.09) | Dividend Share 2.31 | Earnings Share 3.86 | Revenue Per Share 21.753 | Quarterly Revenue Growth 0.006 |
The market value of Bristol Myers Squibb is measured differently than its book value, which is the value of Bristol that is recorded on the company's balance sheet. Investors also form their own opinion of Bristol Myers' value that differs from its market value or its book value, called intrinsic value, which is Bristol Myers' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bristol Myers' market value can be influenced by many factors that don't directly affect Bristol Myers' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bristol Myers' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bristol Myers is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bristol Myers' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.